...
首页> 外文期刊>Biomaterials >In vitro characterization of leukocyte mimetic for targeting therapeutics to the endothelium using two receptors
【24h】

In vitro characterization of leukocyte mimetic for targeting therapeutics to the endothelium using two receptors

机译:使用两个受体的白细胞模拟物的体外表征,用于将治疗剂靶向内皮

获取原文
获取原文并翻译 | 示例

摘要

Selectins (E- and P-selectin) and other endothelial expressed leukocyte adhesion molecules (ELAMs) are potential targets for site-specific delivery of therapeutics to the vascular endothelium due to their specific and highly regulated expression in vascular disease. It was recently shown that degradable microspheres coated with antibodies against E-selectin or other ELAMs can target inflammation in vivo. However, targeting ELAMs alone cannot differentiate between normal and diseased state, as a basal level of these LAMs are expressed on endothelium in healthy tissues. Furthermore, leukocytes usually employ two separate adhesion molecules in parallel to home to diseased tissues, and we recently quantified the advantages of a two-receptor display for the targeting of leukocyte mimetics (Eniola AO, Willcox PJ, Hammer DA. Interplay between rolling and firm adhesion elucidated with a cell-free system engineered with two distinct receptor-ligand pairs. Biophys J 2003;85:2720-31). Here, we describe a leukocyte mimetic for targeting therapeutics to the vasculature in inflammatory diseases via two receptors, selectin and intercellular cell adhesion molecule-1 (ICAM-1), where biodegradable, polymer microspheres were co-functionalized with the selectin ligand, sialyl Lewis(x) (sLe(x)), and an antibody against ICAM-1, anti-ICAM-1 (aICAM-1). These two-receptor targeted particles, at given ratios of sLe(x)/aICAM-1, firmly adhere to substrate surface in flow only when both targeting ligands can interact with their respective receptors, mimicking the multi-step in vivo leukocyte adhesion in inflammation. Thus, we have faithfully recreated the specificity and extent of leukocyte adhesion in a platform that can allow for local delivery of therapeutics. (c) 2005 Elsevier Ltd. All rights reserved.
机译:选择素(E和P选择素)和其他内皮表达的白细胞粘附分子(ELAM)是治疗剂向血管内皮位点特异性递送的潜在靶标,因为它们在血管疾病中的特异性和高度调控表达。最近显示,涂覆有针对E-选择蛋白或其他ELAM的抗体的可降解微球可以靶向体内炎症。但是,仅靶向ELAM不能区分正常状态和患病状态,因为这些LAM的基础水平在健康组织的内皮细胞上表达。此外,白细胞通常采用两个独立的粘附分子,平行于患病组织的家,并且我们最近量化了针对白细胞模拟物(Eniola AO,Willcox PJ,Hammer DA)靶向的两个受体展示的优势。通过用两个不同的受体-配体对工程化的无细胞系统阐明了粘附(Biophys J 2003; 85:2720-31)。在这里,我们描述了一种白细胞模拟物,用于通过两种受体选择素和细胞间细胞粘附分子-1(ICAM-1)将治疗剂靶向炎性疾病中的脉管系统,其中可生物降解的聚合物微球与选择素配体唾液酸路易斯共功能化(x)(sLe(x))和抗ICAM-1的抗体,抗ICAM-1(aICAM-1)。只有当两种靶向配体都可以与各自的受体相互作用时,这些两个受体靶向的颗粒(以sLe(x)/ aICAM-1的给定比例)才能牢固地粘附于基质表面,从而模拟炎症中的多步体内白细胞粘附。因此,我们在平台上忠实地重建了白细胞粘附的特异性和程度,该平台可以局部治疗。 (c)2005 Elsevier Ltd.保留所有权利。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号